Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Rev. esp. cir. oral maxilofac ; 27(2): 100-108, ene.-feb. 2005. ilus, tab
Article in Es | IBECS | ID: ibc-039396

ABSTRACT

El linfoma nasal de células T/ natural killer (NK) (LNT/NK), trashaber recibido múltiples denominaciones, ha sido definido y caracterizadoen el año 2001 por la Organización Mundial de la Salud (OMS), basándoseen una clasificación previa de la Revised European-American LymphomaClassification (REAL), de la manera en que se le conoce actualmente. Suincidencia en el mundo occidental es baja, mientras que en Asia supone elsegundo grupo de linfomas más frecuente, tras los gastrointestinales. Selocaliza preferentemente en las fosas nasales y senos maxilares, mostrandoun curso clínico agresivo, definido por una destrucción de los tejidoscircundantes. Su diagnóstico definitivo se realiza por medio de técnicas dehibridación in situ, llegando a la determinación de su inmunofenotipo. Seha observado una frecuente asociación con el virus de Epstein-Barr (VEB).El pronóstico de esta enfermedad viene definido por el índice pronósticointernacional (IPI) y por el volumen alcanzado por el tumor. A pesar deser radiosensible, su pronóstico es infausto, aconteciendo la muerte delpaciente poco tiempo después del diagnóstico, generalmente como consecuenciade las complicaciones del tratamiento


Nasal T-cell and Natural Killer cell lymphoma (NT/NKL),having been given many names, was defined and described inthe year 2001 by the World Health Organization (WHO), on thebasis of a previous classification by the Revised European-AmericanLymphoma Classification (REAL) as it is known today. Its incidencein the western world is low, while in Asia it represents the secondmost frequent group of lymphomas, followed by the gastrointestinal[lymphoma]. It is typically located in the nasal cavity and maxillarysinuses. It is associated with an aggressive clinical course,characterized by the destruction of surrounding tissue. The definitivediagnosis is made by means of in situ hybridization techniques, inorder to determine the immunophenotype. Its association with theEpstein-Barr virus (EBV) has frequently been observed. The prognosisof this disease is determined by the International Prognosis Index(IPI) and by the size of the tumor. In spite of being responsive toirradiation therapy, its prognosis is gloomy, and the death of thepatient occurs shortly after the diagnosis, generally as a result oftreatment complications


Subject(s)
Female , Aged , Humans , Lymphoma, T-Cell/pathology , Nose Neoplasms/pathology , Killer Cells, Natural/pathology , Herpesvirus 4, Human/pathogenicity , Epstein-Barr Virus Infections/pathology , Lymphoma, T-Cell/drug therapy , Nose Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...